ArticleImmunity2025
Intra-tumoral hypoxia promotes CD8
Abstract read
In one paragraph
Article in Immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Research Advances on the Autophagy and Ferroptosis in the Development and Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Pooled it
- Trial
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Physical Exercise in Immunotherapy.Sports medicine - open · 2026Review
- Metabolic exhaustion and immune ageing in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy.Biomedicines · 2026Review
- Mitochondrial profiling across macrophage states reveals inhibition of IL-4/IL-13 reprogramming by the integrated stress response.Science advances · 2026Article
- ATF4 orchestrates cancer hallmarks: Stress adaptation, metabolic reprogramming and immune suppression.iScience · 2026Review
- ATF4 and FGFR4 cooperatively support thyroid cancer progression and CAF-associated tumor-promoting features.Endocrine · 2026Article
- Review
- Article
- Potential of RAD51C as a hub gene and therapeutic target in bladder cancer: insights from bioinformatics and experimental analysis.International journal of surgery (London, England) · 2026Article
- Stress granule dynamics orchestrate colitis-to-cancer transition via TOM1-mediated disassembly and driven oncogenesis in response to inflammatory oxidative stress.Redox biology · 2026Article
- Integrated hypoxia and metabolic gene signature to predict clinical outcomes and therapeutic vulnerabilities in lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Article
- Mitochondrial transfer between tumor and immune cells: a nexus of metabolic adaptation and immune dysfunction.Biomarker research · 2026Review
- Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8Research square · 2026Article
- Targeting ATF4 overcomes dual resistance to chemo-immunotherapy in gastric cancer by disrupting the DNA damage response.Journal for immunotherapy of cancer · 2026Article
- Hypoxia-inducible factors: Regulatory functions and status as a therapeutic target in gastric cancer (Review).Oncology letters · 2026Review
- T-Cell Exhaustion in the Tumor Microenvironment: Subcellular Dysfunction, Pan-Cancer Characteristics, and Therapeutic Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Coral Del Mar Alicea PaunetoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Brian P RiesenbergLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Evelyn J GandyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew S KennedyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Genevieve T CluttonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jessica W HemLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Katie E HurstLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Elizabeth G HuntLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jarred M GreenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Brian C MillerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Steven P AngusLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gary L JohnsonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Robert J EstherLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Orthopedics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer L GuerrieroDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA; Department of Surgery, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA; Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Peng GaoDepartment of Medicine, Metabolomics Core Facility, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
David R Soto-PantojaDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Robert L FerrisLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer L ModliszewskiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael F ColemanDepartment of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
H Kay ChungLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
J Justin MilnerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stergios J MoschosLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
R Luke WisemanDepartment of Molecular and Cellular Biology, Scripps Research Institute, La Jolla, CA, USA.
Jessica E ThaxtonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: jess_thaxton@med.unc.edu.
Funding
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7MBiomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2MDefining Endoplasmic Reticulum Stress-Development Mitochondria RemodelingRF1NS125674 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI WISEMAN, ROCKLAND LUKE · 2022 to 2022
$2.4MTargeted EGFR for basal subtype pancreatic cancerR01CA288145 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARY L. JOHNSON, Jen Jen Yeh · 2024 to 2026
$1.9MTargeting Chronic ER Stress in T Cells to Improve Cancer ImmunotherapyR01CA244361 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THAXTON, JESSICA E · 2020 to 2024
$1.9MExpoitation of ER Stress Induced Immune Dysfunction to Improve ImmunotherapyR01CA248359 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THAXTON, JESSICA E · 2020 to 2024
$1.7MDefining Endoplasmic Reticulum Stress-Development Mitochondria RemodelingR01NS125674 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI Rockland Luke Wiseman · 2025 to 2026
$1.4MNext-generation T cell therapy: SMARTER T cells for enhanced and durable anti-tumor immunityK01EB034321 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hokyung Kay Chung · 2023 to 2026
$639kNCI NIH HHS R01 CA244361NCI NIH HHS R01 CA248359NCI NIH HHS R01 CA288145NIBIB NIH HHS K01 EB034321NIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544NINDS NIH HHS R01 NS125674NINDS NIH HHS RF1 NS125674
Abstract
Metabolic stress in the tumor microenvironment (TME) promotes T cell dysfunction and immune checkpoint inhibitor (ICI) resistance. We examined the contribution of activating transcription factor 4 (ATF4), the central node of the integrated stress response (ISR), to T cell dysfunction in tumors. CD8
Indexed as
Activating Transcription Factor 4CD8-Positive T-LymphocytesTumor MicroenvironmentAnimalsCell DeathCell HypoxiaCell LineFemaleHumansImmune Checkpoint InhibitorsMaleMiceMice, Inbred C57BLMitochondriaNeoplasmsOxidative StressActivating Transcription Factor 4ATF4 protein, humanAtf4 protein, mouseImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorATF4hypoxiaimmunotherapyintegrated stress responsemetabolismmitochondriaT celltumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.